EMA Validates Marketing Application for Tisotumab Vedotin, A Potential Treatment for Recurrent or Metastatic Cervical Cancer
Feb 3, 2024
Ema Invest Information
Bristol Myers Squibb's Repotrectinib Under EMA Review for NSCLC Treatment
Jan 4, 2024